Introduction: SLE is a systemic autoimmune disease with polyclonal B cell hyperactivity, spontaneous lymphocyte proliferation, and the production of pathogenic antibodies to self-antigens. Interleukin-6 is a pleiotropic cytokine with diverse functions including B-cell growth and differentiation. IL-6 levels have been shown to be affected by single nucleotide change from G to C at position À174 in the promoter region of the IL-6 gene.
Introduction
SLE is a systemic autoimmune disease with extremely diverse clinical presentations and a multitude of clinical symptoms which involves multiple organ systems [1] .
The main features of autoimmunity in SLE are polyclonal B cell hyperactivity, spontaneous lymphocyte proliferation, and the production of pathogenic antibodies to self-antigens. B cell abnormalities in SLE also include excess cytokine production, autoantigen presentation to T cells and modulation of the function of other immune cells [2] . Thus, SLE is generally considered a B cell disease, a theme strengthened by the efficacy of therapies targeting B cells [3] .
Although the initiating immunological event in SLE remains unknown, it has been shown that an imbalance between depressed T H1 cell cytokines which promote cell mediated immunity and enhanced T H2 cell cytokines which support humoral immunity, play a crucial role in the pathophysiological cascade. There is accumulating evidence from experimental and clinical studies to suggest that interleukin-6 (IL-6) is a central cytokine in this context [4] .
Interleukin-6 is a pleiotropic cytokine with diverse functions including stimulation of the hepatic acute phase response to infection and injury [5] , differentiation and/or activation of macrophages and T cells, B-cell growth and differentiation factor that induces the final maturation of IL-4-preactivated Bcell into immunoglobulin-secreting plasma cells, support of multipotential colony formation by hematopoietic stem cells, and neural differentiation [4, 6] .
Interleukin-6 is not constitutively expressed but is highly inducible and is produced in response to a number of inflammatory stimuli such as IL1, platelet-derived growth factor, TNFa, bacterial products such as endotoxin and viral infec-tion. Many cell types produce IL6 in response to noxious stimuli, including monocytes/macrophages, fibroblasts, endothelial cells, adipocytes, T cells, and mast cells [6] .
Higher levels of IL-6 mRNA in SLE PBMC and IL-6 protein in serum and involved kidneys of patients with active disease have been shown and that endogenous IL-6 is essential for SLE B cell hyperactivity [7] [8] [9] . A number of studies have reported a correlation between SLE disease activity and IL-6 [10] . In murine SLE, treatment with anti-IL-6 antibody abrogated disease, supported the concept that IL-6 has an important pathogenic role in lupus [11] .
IL-6 over-expression in SLE could result from an abundance of up-regulating factors and/or polymorphisms in regions having gene regulatory implications, however, several reports are in support of the latter [12] .
The IL-6 gene has been mapped to the short arm of chromosome 7 at location 21-15 [13] . The entire IL-6 gene is organized into five exons and four introns. The translation of IL-6 RNA and post-translational processing results in the formation of a 21-to 28-kDa protein with 128 amino acids [14] . IL-6 is regulated mainly at the transcriptional level by regulatory elements in the 5 0 flanking region of the gene encoding IL-6. Several polymorphisms in the promoter region of IL-6 gene have been described [15] [16] [17] . At this region, À572 G/C and À174 G/C polymorphisms are key regulators of IL-6 gene and downstream protein levels [18] .
The single nucleotide change from G to C at position À174 has been shown to affect IL-6 levels [19] . This polymorphism lies immediately upstream of a multi-responsive element located at positions À173 to À151 relative to the transcription start site. This element has been shown to be important in IL-1 and TNF modulated expression of IL-6 [15, 16] .
In view of these findings, we conducted the study to find out whether single nucleotide polymorphisms located in the promoter region of the IL-6 gene (À174 G/C) constitute a genetic susceptibility for SLE and its association with various disease clinical and immunological features.
Patients and methods

SLE patients and healthy controls
Blood samples (3 ml each) were collected from 42 female SLE patients and 40 healthy volunteers, from the Rheumatology and Rehabilitation and Internal Medicine Departments, Kasr El Aini Hospitals, Cairo University, after taking their consent. The patients satisfied the 1982 revised criteria of the American Rheumatism Association for the classification of SLE [20] , with a mean age of 32.4 ± 5.5 years and mean disease duration of 5.7 ± 1.5 years. The controls were matched for age and sex with a mean age of 31.7 ± 4.9 years. SLE patients' medical histories were reviewed from the disease onset until admission to the study. Clinical and laboratory features were recorded including constitutional, hematological, joint, renal, and neuropsychiatric manifestations, oral ulcers, serositis, malar rash, and photosensitivity and CBC, liver, kidney functions and serum C3 and C4 levels. To investigate autoantibody status; ANAs, Anti-dsDNA and Anti-Sm antibodies were tested.
-CNS disease included: cerebrovascular disease, demyelinating syndrome, aseptic meningitis, myelopathy, seizures, cognitive dysfunction, psychosis and mood disorders [21] . Lupus nephritis was defined by the presence of persistent 24-h proteinuria >0.5 g and/or active sediment (cellular casts-red cell, granular, tubular, or mixed) and/or serum creatinine >1.2 mg/dl and/or renal biopsy evidence of lupus nephritis (immune complex deposition). WHO criteria were used to classify the histopathological findings [22] .
The healthy controls were unrelated to patients and belonged to the same ethnic background and shared similar social conditions to the patients. Exclusion criteria; significant cardiovascular, pulmonary, metabolic, rheumatic, renal diseases and other diseases with a known genetic or hereditary predisposition.
IL-6. (À174 G/C) genotyping
Genomic DNA was extracted from the whole blood using EZ-10 spin column Blood Genomic DNA Minipreps kit (Biosystems, California, US) and stored at À20°C until genotyping was performed.
Genotyping of the single nucleotide polymorphisms in the promoter region of the IL-6 gene (À174 G/C) was carried out by polymerase chain reaction. Primer sequences (forward primer G: 5 0 -GCACTTTT CCCCCTAGTTGTGTCTTACG-3 0 ; forward primer C: 5 0 -ATGACGACCTAAGCTTTACTTT TCCCCCTAGTTGTGT CTTGAC-3 0 ; and reverse primer: 5 0 -ATAAATCTTTGTTGGAGGGTGAGG-3 0 ) were used. Each PCR contained 10 ng genomic DNA in a final volume of 20 ll reaction which included 10 pmol of each primer (Operon Biotechnologies, Germany), 1 U Taq DNA polymerase (Promega Corporation, US,), 0.1 mM dNTP mix (Promega Corporation, US,), 2.0 ll Taq buffer with KCl, and 1.0 mM MgCl 2 . PCR was performed on an automated DNA thermal cycle (Peq lab, Biotechnologie) with procedure as follows: initial denaturation at 95°for 10 min, 40 cycles of amplification consisting of denaturation at 94°C for 30 s, annealing at 66°C for 45 s, extension at 72°C for 45 s, extension at 72°C for 45 s and in the last cycle, extension was prolonged to 7 min [4] . The amplified products were then visualized by 4% agarose gel electrophoresis and visualized on an ultraviolet transilluminator to detect the genotype distribution and allelic frequencies of the polymorphisms, as represented in Fig. 1 .
Statistics. The results were analyzed using SPSS computer software package, version 10.0 (Chicago, IL, USA). All data were expressed as frequencies or mean and SD. Comparison of quantitative data was done using student's t-test. The differences in genotype and allele frequencies & their associations with SLE clinical and immunological features were compared by Chi-square (v 2 ) and Fisher's exact tests. Odd's ratio (OR) and 95% confidence interval (CI) values were calculated. P value of <0.05 was taken as significant.
Results
Clinical data and SLE patients' characteristics are summarized in Table 1 .
IL-6 promoter polymorphism (À174 G/C) in SLE patients compared to controls
As represented in Table 2 , evaluation of genotypic and allelic distributions showed no significant difference between SLE patients and controls. Of the patients, 71.4% had the GG genotype (70% in the control group), 23.8% had the GC genotype (30% in the control group) and 4.8% had the CC genotype (0% in the control group). The frequency of G allele was higher than C allele in both patients (83.3% vs. 16 .7%) and controls (85% vs. 15%). 
IL-6 promoter polymorphism (À174 G/C) and clinical and laboratory manifestations of SLE
GG genotype and G allele were associated with significantly higher frequencies and increased risk of: constitutional manifestations at disease onset, photosensitivity, hematological disorders and positivity of ANAs and Anti-dsDNA as shown in details in Tables 3 and 4 .
Furthermore, no significant difference was found between IL-6 genotypes concerning SLE laboratory features except for WBCs counts as patients with GG genotype had significantly lower mean compared to SLE patients with (GC and CC) genotypes (P = 0.002), as shown in Table 5 .
IL-6 promoter polymorphism (-174 G/C) and Lupus nephritis
Twenty-five patients had lupus nephritis (LN) proved by renal biopsy but none of them had CC genotype. LN patients with GG genotype had nearly similar mean 24-h proteinuria to those with GC genotype (2.93 ± 1.07 vs. 2.68 ± 1.06 g/24 h and P = 0.39).
On assessment of the association between the IL-6 genotypes and the histological WHO classes, no significant difference was found in IL-6 genotype and allele distributions when patients with diffuse proliferative glomerulonephritis (class IV), which has the worst prognostic outcome, were compared to patients with non-class IV glomerulonephritis (classes II and III), as represented in Table 6 . GG genotype's and G allele's OR in patients with class IV LN was 0.23 (95% CI 0.04-1.51); 0.3 (95% CI 0.05-1.68), respectively.
Discussion
Recent immunogenetic studies demonstrated that polymorphisms at several loci, including the major histocompatibility complex, complement proteins, immunoglobulin receptors, cytokines and other as yet unmapped genes, are associated with SLE, implying that the gene products of these loci are involved in the pathogenesis of SLE [23] .
In addition, clinical and experimental data suggest the IL-6 locus to be further candidate gene for SLE. Thus, IL-6 has been shown to promote many immunopathological features typical of SLE, such as polyclonal B-cell hyperactivity and the production of autoantibodies. Moreover, IL-6 can be detected in compartments involved in active disease [4] .
GG homozygotes and G/C heterozygotes have been demonstrated to have higher plasma IL-6 level, higher gene transcriptional activity, and higher inducible IL-6 responses than CC homozygous in systemic-onset juvenile chronic arthritis. The reduced frequency of the potentially protective CC genotype in young patients may contribute to its pathogenesis [19] .
In Primary Sjo¨gren syndrome, the G/C polymorphism of IL-6 gene didn't predispose patients to the disease. The G allele seemed partly to determine the plasma level of IL-6, suggesting that the presence of this allele may be a risk factor for some extraglandular manifestations associated with high IL-6 concentration [24] .
In the present work, genotypic and allelic distributions of IL-6 promoter region (À174 G/C) polymorphism showed no significant difference between SLE patients and controls. This finding is explained either by that fact this polymorphism plays no role in disease susceptibility or that SLE patients display heterogeneity of their genetic background that masks its effect [4, 12] .
Furthermore, it has been suggested that single nucleotide polymorphisms at distinct polymorphic sites influence each other and do not act independently of one another; thus, the cooperative influence of genetic polymorphisms on development of disease should also be considered [25] . In literature, several studies revealed contradictory results regarding the relationship between IL-6 promoter region (À174 G/C) polymorphism and SLE. The frequency of IL-6 (GG and GC) genotypes and G allele were demonstrated to be significantly higher in SLE patients than controls [26] . Moreover, homozygous G genotype patients were observed to be predisposed to SLE development and those with heterozygous G/C genotype could be protected from developing SLE [27] . On the other hand, a number of studies reported lack of association of the IL-6 gene polymorphism at position À174 with SLE [4, 18, 28] .
The current study shows that GG genotype and G allele were associated with significantly higher frequencies and increased risk of: constitutional manifestations at disease onset, photosensitivity, hematological disorders and positivity of ANAs and Anti-dsDNA compared to (GC and CC) genotypes and C allele. This data suggest that the C allele has a masking effect over the G allele in G/C heterozygous, which may be due to a complex interaction of both alleles when present co-dominantly as explained by Chau and coworkers [27] .
The study was performed on Caucasian German patients with SLE, IL-6 promoter polymorphisms at À174 G/C predisposed to distinct clinical and immunological features such as discoid skin lesions and the production of anti-histone antibodies in association with IL-6 high-responder allele (À174 G) [4] . In the Iranian study, À174 G/C polymorphism was associated with the presence of antinuclear antibodies (in all patients) and rash and hematuria (in male patients) concluding that IL-6 À174 GG is important for the production of diseaseassociated autoantibodies and some clinical manifestations particularly in male patients [18] .
In Chinese SLE patients, there were no significant differences in IL-6 gene polymorphism between the SLE patients concerning their clinical manifestations [28] . These controversial results can be explained by the genetic heterogeneity of SLE in different populations [29] .
Although IL-6 has been found in cerebrospinal fluid of SLE patients with active CNS disease & in urine samples and kidney biopsies of LN patients, in agreement with the findings of Schott and associates [4] , we did not find an association of IL-6 promoter region (À174 G/C) polymorphism with neuropsychiatric lupus, lupus nephritis or its severity. This may has been due to the small number of patients with CNS lupus included in our study. In addition, the existence of other potent genetic regulatory elements or the non-specific IL-6 production under inflammatory conditions or the modulated IL-6 production by hormones, other cytokines and immuno-modulating therapy may be even more important reasons [4] .
In conclusion, our data demonstrates that IL-6 promoter region (À174 G/C) polymorphism does not confer susceptibility to SLE but predisposes to constitutional manifestations at disease onset, photosensitivity, hematological disorders and the production of ANAs and Anti-dsDNA. Furthermore, the increased frequency of the high-response G allele suggests that a genetically determined high IL-6 response may have a pathogenic role under these conditions. 
